NewLink Genetics Corporation Reports Second Quarter 2014 Financial Results
"We continue to expand our clinical development efforts with additional promising HyperAcute and IDO pathway inhibitor product candidates from our pipeline. This includes additional studies combining our IDO pathway product candidates with treatment modalities including other checkpoint inhibitors, chemotherapy, and our own HyperAcute immunotherapies. Furthermore, we are in the early stages of building our commercial footprint in our new facility in
"The diversity of our clinical development program was highlighted at the recent 50th annual ASCO meeting by a series of nine presentations demonstrating progress with our IDO pathway inhibitors, indoximod and
"We were particularly pleased to present additional demographic data for all 722 patients from our IMPRESS study demonstrating a high level of comparability to historical data from other large U.S.-based phase 3 resected pancreatic cancer studies. We also presented data that nearly half (31/64) of the patients in our phase 2 trial of algenpantucel-L had increased expression of anti-calreticulin antibody that correlated with an increase in overall survival. This was particularly important because the increase in overall survival was statistically significant even though the study only evaluated anti-calreticulin expression in a limited number of patients."
NewLink reported a net loss of
Research and development expense in the second quarter of 2014 was
General and administrative expense in the second quarter of 2014 was
NewLink ended the quarter on
Recent Accomplishments
- Entered into a Development and Manufacturing Agreement with a contractor to, among other things, increase the potential commercial manufacturing capacity of HyperAcute® product candidates.
-
HyperAcute Platform. Presented data at the
American Society of Clinical Oncology (ASCO) 2014 Annual Meeting in the following poster presentations or discussions:- Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer.
- A phase 2b study of ipilimumab with or without dorgenmeltucel-L (HyperAcute-Melanoma) immunotherapy for patients with stage IV melanoma.
- An open-label, randomized phase 2b active control study of second-line tergenpumatucel-L immunotherapy versus docetaxel in patients with progressive or relapsed non-small cell lung cancer (NSCLC).
-
IDO Inhibitors. Presented data at the
American Society of Clinical Oncology (ASCO) 2014 Annual Meeting in the following poster presentations or discussions:- Phase 1/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus ipilimumab for the treatment of unresectable stage 3 or 4 melanoma.
- A phase 1/2 study of the combination of indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors.
-
First in human phase 1 study of the novel indoleamine-2,3-dioxygenase (IDO) inhibitor
NLG919 . - A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer.
- A phase 2 study of Ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors.
- A randomized, double-blind phase 2 study of sipuleucel-T followed by indoximod or placebo in the treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.
- TDO Inhibitors. Continued preclinical testing directed at selection of a clinical candidate from a novel class of compounds that mediate TDO (tryptophan-2,3-dioxygenase).
About
NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit http://www.linkp.com.
By leveraging its dual cancer immunotherapy platforms, which are designed to harness multiple components of the immune system to combat cancer, NewLink is well positioned to establish a leadership position in immuno-oncology. NewLink's HyperAcute immunotherapy platform uniquely stimulates the patient's immune system to recognize and attack cancer cells, while its IDO pathway inhibitor platform technology targets a key immune checkpoint and disrupts mechanisms by which tumors evade the patient's immune system. NewLink's broad product pipeline includes biologic and small molecule immunotherapy product candidates designed to treat a wide range of oncology indications either as monotherapy or in combination with other treatment regimens. NewLink's most advanced product candidates include algenpantucel-L and tergenpumatucel-L HyperAcute immunotherapies, currently in Phase 3 clinical development for pancreatic cancer and Phase 2b/3 for non-small cell lung cancer, respectively. The IDO pathway inhibitor platform has two drug candidates currently in development. The first, indoximod, is currently in Phase 2 development for a range of solid tumor cancers. NewLink's second IDO pathway inhibitor,
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about: NewLink's financial guidance for 2014; enrollment in its clinical trials for product candidates based on NewLink's HyperAcute and IDO platform technologies; its timing of release of clinical data from ongoing clinical studies; its plans related to moving additional indications into clinical development; NewLink's future financial performance, results of operations, cash position and sufficiency of capital resources to fund its operating requirements; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink's Annual Report on Form 10-K for the year ended
|
|
||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Grant revenue | $ | 212 | $ | 232 | $ | 546 | $ | 534 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 6,475 | 5,037 | 12,863 | 11,380 | ||||||||||||
| General and administrative | 2,863 | 2,264 | 6,114 | 4,265 | ||||||||||||
| Loss from operations | (9,126 | ) | (7,069 | ) | (18,430 | ) | (15,111 | ) | ||||||||
| Other (expense) income, net | (37 | ) | (8 | ) | 31 | 100 | ||||||||||
| Net loss | $ | (9,163 | ) | $ | (7,077 | ) | $ | (18,399 | ) | $ | (15,011 | ) | ||||
| Net loss per common share, basic and diluted | $ | (0.33 | ) | $ | (0.28 | ) | $ | (0.66 | ) | $ | (0.61 | ) | ||||
| Weighted average number of common shares outstanding | 27,876,652 | 25,620,566 | 27,742,029 | 24,745,380 | ||||||||||||
|
|
|||||||||||
| Condensed Consolidated Balance Sheets | |||||||||||
| (unaudited) | |||||||||||
| (In thousands, except share and per share data) | |||||||||||
|
|
|
||||||||||
| 2014 | 2013 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash, cash equivalents and certificates of deposit | $ | 77,110 | $ | 61,540 | |||||||
| Prepaid expenses and other current assets | 1,104 | 2,430 | |||||||||
| Total current assets | 78,214 | 63,970 | |||||||||
| Property and equipment, net | 6,456 | 6,586 | |||||||||
| Total assets | $ | 84,670 | $ | 70,556 | |||||||
| Liabilities and Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable and accrued expenses | $ | 3,578 | $ | 3,473 | |||||||
| Other current liabilities | 280 | 403 | |||||||||
| Total current liabilities | 3,858 | 3,876 | |||||||||
| Long-term liabilities: | |||||||||||
| Royalty obligation payable | 6,000 | 6,000 | |||||||||
| Notes payable and obligations under capital leases | 937 | 1,033 | |||||||||
| Deferred rent | 1,279 | 1,321 | |||||||||
| Total long-term liabilities | 8,216 | 8,354 | |||||||||
| Total liabilities | 12,073 | 12,230 | |||||||||
| Stockholder's equity: | |||||||||||
| Common stock | 279 | 266 | |||||||||
| Additional paid-in capital, net | 226,876 | 194,038 | |||||||||
| Treasury Stock, at cost | (182 | ) | - | ||||||||
| Retained Deficit | (154,376 | ) | (135,977 | ) | |||||||
| Total equity | 72,597 | 58,326 | |||||||||
| Total liabilities and equity | $ | 84,670 | $ | 70,556 | |||||||
Contact:
Chief Financial Officer
515-598-2561
Investor@linkp.com
Source:
News Provided by Acquire Media